Exenatide

Generic Name: Exenatide

Brand Names: Bydureon, Byetta

Drug Type: Biotech

CAS Number: 141758-74-9

Unique Ingredient Identifier: 9P1872D4OL

Background: Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations. Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available.

Indication: Exenatide is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. An extended-release formulation is available which is indicated in patients ≥10 years old, while the immediate-acting formulation is approved only for adult patients.

Associated Conditions: Type 2 Diabetes Mellitus

Clinical Trials

Research of Intensive Metabolic Intervention Before Pregnancy in PCOS

Phase 4

Conditions: PCOS
Impaired Glucose Tolerance

Interventions: Drug: Orlistat
Drug: Exenatide
Drug: Acarbose 100 MG
Drug: Metformin

First Posted Date: 2017-12-26

Last Posted Date: 2017-12-26

Lead Sponsor: RenJi Hospital

Target Recruit Count: 160

Registration Number: NCT03383068

Locations: 🇨🇳
Renji Hospital Department of Endocrinology and Metabolism, Shanghai, Shanghai, China

DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus
Obesity

Interventions: Drug: Dapagliflozin 10mg
Drug: Exenatide
Other: placebo exenatide
Other: placebo dapagliflozin

First Posted Date: 2017-12-04

Last Posted Date: 2021-06-11

Lead Sponsor: Amsterdam UMC, location VUmc

Target Recruit Count: 65

Registration Number: NCT03361098

Locations: 🇳🇱
Amsterdam UMC, location VU Medical Center, Amsterdam, Noord-Holland, Netherlands

Research of Exenatide for Overweight/Obese PCOS Patients With IGR

Phase 4

Completed

Conditions: Overweight and Obesity
Disorder of Glucose Regulation
Polycystic Ovary Syndrome

Interventions: Drug: Exenatide
Drug: Metformin

First Posted Date: 2017-11-24

Last Posted Date: 2019-09-11

Lead Sponsor: RenJi Hospital

Target Recruit Count: 183

Registration Number: NCT03352869

Locations: 🇨🇳
Renji Hospital Department of Endocrinology and Metabolism, Shanghai, China

Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: Exenatide
Drug: Exenatide and Dapagliflozin
Drug: Dapagliflozin

First Posted Date: 2017-11-06

Last Posted Date: 2023-07-24

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Target Recruit Count: 107

Registration Number: NCT03331289

Locations: 🇺🇸
University Health System Texas Diabetic Institute, San Antonio, Texas, United States

Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients With Newly Diagnosed Type 2 Diabetes

Phase 4

Completed

Conditions: Type2 Diabetes

Interventions: Drug: Exenatide or metformin hydrochloride

First Posted Date: 2017-09-29

Last Posted Date: 2017-10-02

Lead Sponsor: Beijing Chao Yang Hospital

Target Recruit Count: 230

Registration Number: NCT03297879

Trial of EXenatide in Acute Ischaemic Stroke

Phase 2

Conditions: Acute Ischemic Stroke

Interventions: Drug: Exenatide Injection

First Posted Date: 2017-09-19

Last Posted Date: 2021-09-14

Lead Sponsor: Neuroscience Trials Australia

Target Recruit Count: 350

Registration Number: NCT03287076

Locations: 🇦🇺
Austin Hospital, Heidelberg, Victoria, Australia
🇦🇺
Royal Melbourne Hospital, Parkville, Victoria, Australia
🇫🇮
Helsinki University Hospital, Helsinki, Finland

and more 12 locations